Lessons from studies of antigen-specific T cell responses in multiple sclerosis

Journal of Neural Transmission, Supplement

Volumn , Issue 60, 2000, Pages 361-373

  Martin, R ^a   Bielekova, B ^a   Gran, B ^a   McFarland, H F ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; MYELIN BASIC PROTEIN; MYELIN PROTEIN; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CONFERENCE PAPER; DEMYELINATION; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0034517786     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6301-6_26     Document Type: Conference Paper

References (103)

1. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat
2. Identification of a major encephalitogenic epitope of proteolipid protein (residues 56-70) for the induction of experimental allergic encephalomyelitis in Biozzi AB/H and nonobese diabetic mice
3. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice
4. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype
5. Genetic analysis of experimental allergic encephalomyelitis in mice
6. Oligodendrocyte-specific expression and auto-antigenicity of transaldolase in Multiple Sclerosis
7. Hypothesis: A possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis
8. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases
9. Dynamics of autoimmune T cell infiltration: Reversal of paralysis and disappearance of inflammation following treatment of experimental encephalomyelitis with a myelin basic protein peptide analog
10. Lymphotoxin and tumor necrosis factoralpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity
11. New genetic loci that control susceptibility and symptoms of experimental allergic encephalomyelitis in inbred mice
12. The genetic epidemiology of Multiple Sclerosis
13. Induction of Th1 and Th2 CD4+ T cell responses: The alternative approaches
14. Inflammatory infiltrates in experimental axonal ion channel encephalitis (EAICE)
15. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor
16. A full genome search in Multiple Sclerosis
17. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein
18. QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing IL2
19. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand
20. Suppression and reversal of allergic encephalomyelitis in rhesus monkeys with basic protein and peptides
21. Encephalitogenic epitopes of myelin basic protein
22. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms
23. Antibody facilitation of Multiple Sclerosis-like lesions ina nonhuman primate
24. Identification of autoantibodies associated with myelin damage in Multiple Sclerosis
25. Repertoire dynamics of autoreactive T cells in Multiple Sclerosis patients and healthy subjects: Epitope spreading versus clonal persistence
26. A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis
27. Encephalitogenicity of murine, but not bovine, DM20 in SJL mice is due to a single amino acid difference in the immunodominant encephalitogenic epitope
28. A complete genomic screen for Multiple Sclerosis underscores a role for the major histocompatibility complex. The Multiple Sclerosis genetics group
29. Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotype
30. Biotechnological agents of the immunotherapy of Multiple Sclerosis. Principles, problems and perspectives
31. Myelin-associated oligodendrocytic basic protein: Identification of an encephalitogenic epitope and association with Multiple Sclerosis
32. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and tumor necrosis factor α production
33. Allergic encephalomyelitis: Isolation of an encephalitogenic peptide active in the monkey
34. The central nervous sytem-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in Multiple Sclerosis (MS)
35. Reactivity to myelin antigens in Multiple Sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein
36. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: Preliminary analysis of MOG T cell epitopes
37. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100β molecule, a calcium binding protein of astroglia
38. Visualization of myelin basic protein (MBP) T cell epitopes in Multiple Sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex
39. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire
40. Genomewide scan of Multiple Sclerosis in Finnish multiplex families
41. Multiple Sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein
42. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein
43. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system
44. B lymphocytes producing demyelinating autoantibodies: Development and function in gene-targeted transgenic mice
45. Encephalitogenicity of myelin-associated oligodendrocyte basic protein and 2′,3′-cyclic nucleotide 3′-phosphodiesterase for Balb/c ans SJL mice
46. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor
47. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans
48. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with Multiple Sclerosis
49. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from Multiple Sclerosis patients and healthy individuals
50. Immunological aspects of demyelinating diseases
51. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis
52. Multiple Sclerosis (part 1)
53. Multiple Sclerosis (part 2)
54. Myelin basic protein-specific T lymphocyte repertoire in Multiple Sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones
55. Immunodominance of a low-affinity MHC binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire
56. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis
57. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent experimental autoimmune encephalomyelitis induced by multiple myelin antigens
58. T cell determinants of myelin basic protein include a unique encephalitogenic I-E-restricted epitope for Lewis rats
59. Selection for T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis
60. Primarily chronic progressive and relapsing/remitting multiple sclerosis: Two immunogenetically distinct disease entities
61. Autoreactive T lymphocytes in Multiple Sclerosis determined by antigen-induced secretion of interferon-γ
62. T-cell recognition of an immunodominant myelin basic protein epitope in Multiple Sclerosis
63. Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytolytic CD4+ T cells from Multiple Sclerosis
64. Identification of a second T cell epitope of human proteolipid protein (residues 89-106) recognized by proliferative and cytolytic CD4+ T cells from multiple patients
65. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals
66. Myelin autoreactivity in Multiple Sclerosis: Recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors
67. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vivo activation of lymph node cells by myelin basic protein: Requirement for Lyt-1+2- T lymphocytes
68. Multiple Sclerosis: Immune system molecule expression in the central nervous system
69. Evidence for multiple human T cell recognition sites on myelin basic protein
70. Human cytotoxic T-cell recognition of a synthetic peptide of myelin basic protein
71. 2′, 3′-cyclic nucleotide 3′-phosphodiesterase: A novel candidate autoantigen in demyelinating diseases
72. Mast cell specific proteases in rat brain: Changes in rats with experimental allergic encephalomyelitis
73. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins
74. Predominant and stable T cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis
75. A genome screen in Multiple Sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22
76. Mast cells are essential for early onset and severe disease in a murine model of Multiple Sclerosis
77. Induction of Multiple Sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein
78. Induction of T-cell anergy by altered T cell receptor ligand on live antigen-presenting cells
79. Multiple Sclerosis: A coordinated immunological attack against myelin in the central nervous system
80. Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice
81. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of Multiple Sclerosis pathology
82. T and B cell responses to myelin-oligodendrocyte glycoprotein in Multiple Sclerosis
83. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes
84. Encephalitogenic and immunogenic potential of the stress protein alphaB-crystallin in Biozzi ABH (H-2A(g7)) mice
85. Peripheral blood mononuclear cells from Multiple Sclerosis patients recognize myelin proteolipid protein and selected peptides
86. Myelin proteolipid protein-induced experimental allergic encephalomyelitis. Variations of disease expression in different strains of mice
87. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice
88. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and Multiple Sclerosis
89. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from Multiple Sclerosis patients
90. The role of anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages
91. The small heat-shock protein αB-crystallin as candidate autoantigen in Multiple Sclerosis
92. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis
93. Patients with Multiple Sclerosis carry DQB1 genes which encode shared polymorphic aminoacid sequences
94. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99)
95. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells
96. Fine specificity of the antibody response to myelin basic protein in the central nervous system in Multiple Sclerosis: The minimal B-cell epitope and a model of its features
97. Animal models
98. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand
99. Antigen recognition in autoimmune encephalomy- elitis and the potential for peptide-mediated immunotherapy
100. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2 restricted T cell clones from Multiple Sclerosis patients: Identity of key contact residues in the B-cell and T-cell epitopes
101. The T lymphocyte in experimental allergic encephalomyelitis
102. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein in peripheral blood and cerebrospinal fluid of patients with Multiple Sclerosis
103. Identification of an N-terminally acetylated encephalitogenic epitope in myelin proteolipid apoprotein for the Lewis rat